Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UCBMEX:UCBN 95 EV-to-FCF is 33.16 as of Aug. 12, 2026, which is 46% above its 10-year median of 22.77. GuruFocus rates MEX:UCBN with a GF Score™ of 95/100 and a GF Value™ of MXN1,905.79. Among 332 Biotechnology companies, UCB ranks worse than 69.28% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, UCB's Enterprise Value is MXN900,945 Mil.
UCB's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was MXN27,168 Mil. Therefore, UCB's EV-to-FCF for today is 33.16.
The historical rank and industry rank for UCB's EV-to-FCF or its related term are showing as below:
MEX:UCBN'
s EV-to-FCF Range Over the Past 10 Years
Min: 8.14 Med: 22.77 Max: 88.96
Current: 34.97
During the past 13 years, the highest EV-to-FCF of UCB was 88.96. The lowest was 8.14. And the median was 22.77.
MEX:UCBN's EV-to-FCF is ranked worse than 69.28% of 332
companies
in the Biotechnology industry
Industry Median: 17.465
vs MEX:UCBN: 34.97
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-08-12), UCB's stock price is MXN1692.27.
UCB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was MXN233.012. Therefore, UCB's PE Ratio (TTM) for today is 7.26.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
UCB's share price for today is MXN1692.27.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. UCB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was MXN233.012.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
UCB EV-to-FCF Related Terms
UCB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for UCB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:UCBN vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, UCB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UCB EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UCB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where UCB's EV-to-FCF falls into.
UCB's current Enterprise Value is MXN900,945 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. UCB's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was MXN27,168 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UCB (MEX:UCBN) has a EV-to-FCF of 33.16 as of Aug. 12, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on UCB and its competitors. This is 46% above median its historical median of 22.77. Over the past decade, UCB's EV-to-FCF has ranged from 8.14 to 88.96. According to the industry distribution chart, UCB ranks #230 out of 332 companies in the Biotechnology industry, placing it in the top 69.3%.
Is UCB's EV-to-FCF too high?
UCB's current EV-to-FCF of 33.16 is 46% above median its 10-year median of 22.77. Over the past 10 years, this metric has ranged from a low of 8.14 to a high of 88.96. The Biotechnology industry median EV-to-FCF is 17.47. UCB's value of 33.16 is 89.9% above this industry median. Based on the distribution chart, UCB ranks #230 out of 332 companies in the Biotechnology industry, which is below the industry midpoint. Overall, UCB has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does UCB's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UCB ranks #230 out of 332 companies for EV-to-FCF. This places UCB in the lower half of its industry. The industry median EV-to-FCF is 17.47. UCB's value of 33.16 is 89.9% above this benchmark. Historically, UCB's own EV-to-FCF has ranged from 8.14 to 88.96 over the past decade. While the company's 10-year median is 22.77 vs. the industry median of 17.47, UCB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 17.47, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UCB's current EV-to-FCF of 33.16 is 89.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on UCB and its competitors. For the Biotechnology industry, the median EV-to-FCF is 17.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UCB's current EV-to-FCF is 33.16, which is 46% above median its own 10-year median of 22.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
UCB (MEX:UCBN) has a current EV-to-FCF of 33.16. The stock's GF Value™ is MXN1,905.79, compared to a current price of MXN1,692.27 — trading 11.2% below its estimated fair value. The current EV-to-FCF is 33.16, which is 46% above median its 10-year median of 22.77 and 89.9% above the Biotechnology industry median of 17.47. UCB's overall GF Score™ is 95/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For UCB (MEX:UCBN), the current EV-to-FCF is 33.16 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UCB (MEX:UCBN) Overvalued in 2026?
Based on GuruFocus' analysis, UCB stock appears to be undervalued.
The current stock price of MXN1,692.27 is trading 11.2% below its estimated GF Value™ of MXN1,905.79.
Key valuation signals for MEX:UCBN:
EV-to-FCF: 33.16 (46% above median its 10-year median of 22.77)
GF Value™: MXN1,905.79 vs. price of MXN1,692.27 (11.2% below fair value)
Industry Position: 89.9% above the Biotechnology median (#230 of 332)
No single metric tells the full story. See the MEX:UCBN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
95GF Score
Get the complete analysis for MEX:UCBN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:UCBN has been successfully added to your 
